- Research article
- Open Access
A secretory phospholipase A2-mediated neuroprotection and anti-apoptosis
© Armugam et al; licensee BioMed Central Ltd. 2009
- Received: 7 May 2009
- Accepted: 23 September 2009
- Published: 23 September 2009
Phospholipase A2 liberates free fatty acids and lysophospholipids upon hydrolysis of phospholipids and these products are often associated with detrimental effects such as inflammation and cerebral ischemia. The neuroprotective effect of neutral phospholipase from snake venom has been investigated.
A neutral anticoagulant secretory phospholipase A2 (nPLA) from the venom of Naja sputatrix (Malayan spitting cobra) has been found to reduce infarct volume in rats subjected to focal transient cerebral ischemia and to alleviate the neuronal damage in organotypic hippocampal slices subjected to oxygen-glucose deprivation (OGD). Real-time PCR based gene expression analysis showed that anti-apoptotic and pro-survival genes have been up-regulated in both in vivo and in vitro models. Staurosporine or OGD mediated apoptotic cell death in astrocytoma cells has also been found to be reduced by nPLA with a corresponding reduction in caspase 3 activity.
We have found that a secretory phospholipase (nPLA) purified from snake venom could reduce infarct volume in rodent stroke model. nPLA, has also been found to reduce neuronal cell death, apoptosis and promote cell survival in vitro ischemic conditions. In all conditions, the protective effects could be seen at sub-lethal concentrations of the protein.
- Middle Cerebral Artery Occlusion
- Infarct Volume
- Astrocytoma Cell
- Epithelial Growth Factor Receptor
- Reduce Infarct Volume
Phospholipase A2 (PLA2; EC 18.104.22.168) forms a diverse class of enzymes with regard to structure, function, localization and regulation. The enzyme catalyzes the hydrolysis of the sn-2 fatty-acyl bond of phospholipids to liberate free fatty acids and lysophospholipids . Major groups of phospholipase A2 that have been actively studied in mammalian systems include a) cytosolic Ca2+-dependent (cPLA2) or Ca2+-independent (iPLA2) [2, 3] and b) Ca2+-dependent secretory (sPLA2) phospholipase A2. Both the cPLA2 and iPLA2 are high molecular weight (85-110 kDa) intracellular enzymes  and they have been widely associated with multifaceted network of signaling pathways. However, PLA2 that acts on membrane phospholipids has been implicated in cell death and differentiation as well as intracellular membrane trafficking .
In mammalian cells, PLA2 activity has been found to increase in response to numerous stimuli such as osmotic challenge, oxidative stress, ischemic conditions and exposure to allergens. The synthesis of different cell specific sub-types and activation of mammalian PLA2 are associated with cell injury and various pathophysiological conditions . In the central nervous system (CNS), PLA2 is known to participate in many (patho)physiological activities [5, 7] and has been found to increase significantly following spinal cord injury . The role of PLA2 has also been documented in schizophrenia, brain trauma and Alzheimer's disease [8, 9] besides global and focal ischemia in animal models . Hippocampal slices subjected to oxygen and glucose deprivation (OGD) have been found to show an increase in PLA2 activity and a concomitant death of neuronal cells. Inhibition of cPLA2 has been found to result in an enhanced survival of the hippocampal neurons . Evidently, cPLA2 knock-out mice subjected to focal cerebral ischemia showed significant reduction in infarct volume and the extent of neurological impairment . Furthermore, Strokin et al  demonstrated that inhibition of iPLA2 during OGD could render neuroprotection to the hippocampal slice cultures. Furthermore, simultaneous inhibition of cPLA2 and sPLA2 activities have also been shown to improve survival of glial cells subjected to ischemic injury .
The snake venom PLA2 belongs to the Ca2+-dependant secretory PLA2. Venom phospholipases A2 possess an enzymic activity and a wide variety of (patho)pharmacological activities such as antiplatelet, anticoagulant, hemolytic, neurotoxic (presynaptic), myotoxic, edema-inducing, hemorrhagic, cytolytic, cardiotoxic as well as an ability to bind antagonistically to muscarinic acetylcholine receptor (mAChR) [15–17]. The snake venom phospholipases are divided into two main groups, group I and group II, based on their primary structures . The group I PLA2 is found in abundance in the venom of cobras, kraits and sea snakes, while group II PLA2 is common in vipers and pit vipers. The cobra venom PLA2 belongs to group IA that is similar to the pancreatic type group IB protein but without the signature pancreatic loop structure. Venom of Naja sputatrtix, a Malayan spitting cobra, comprises of three isoforms (2 neutral and 1 acidic) of group 1A PLA2. One of the neutral forms, nPLA-1 (nPLA) is a highly potent anticoagulant protein that exhibits relatively high enzymic activity [18–20]. This protein has also been shown to possess an ability to bind to all muscarinic receptor subtypes (m1-5) with a higher affinity to the m5 subtype .
In this report, in contrast to the reported detrimental effects of mammalian phospholipase A2 to the central nervous system, we demonstrate that neutral PLA2 (nPLA) from Naja sputatrix could reduce neuronal cell death and afford neuroprotection to rat brain subjected to transient focal ischemia. Furthermore, OGD induced tissue injury has also been found to be reduced in the presence of nPLA. Real-time quantitative gene expression analysis showed that the pro-survival and anti-apoptotic genes have been upregulated. Both caspase 3 (in vitro, cell culture) and TUNEL (in vivo, brain slices) assays showed that apoptotic cell death can be reduced upon treatment with nPLA.
Purification of nPLA
Phospholipase A2 (nPLA) was purified from Naja sputatrix crude venom (Sigma Chemicals Co., USA) using Sephadex G-100 gel filtration followed by reverse phase high performance liquid chromatography (RP-HPLC). The protein fractions were characterized as described by Armugam et al  and quantitated using the Bradford assay (Bio-Rad Laboratories, CA).
Transient focal cerebral ischemia
Male Sprague-Dawley rats (200-300 g) were obtained from the Laboratory Animal Centre (National University of Singapore, Singapore) and maintained on an ad libitum intake of standard laboratory chow and drinking water. All animals were handled according to the guidelines given by the Council for International Organization of Medical Sciences (CIOMS) on animal experimentation (WHO, Geneva, Switzerland) and the National University of Singapore (IACUC/NUS) guidelines for handling laboratory animals. Animals were anaesthesized and left middle cerebral artery occlusion (MCAo) was performed as described by Longa et al . The occlusion was confirmed with the real-time measurement of cerebral blood flow (CBF) in the territory of the middle cerebral artery (MCA) using the Laser-Doppler flowmetry (OxyFlo, Oxford Optronix) and the signals were digitized using a 4-channel Powerlab 4SP (ML760) and recordings were displayed with Chart 5 software (ADInstruments Pty Ltd, Australia). Reperfusion was initiated by suture withdrawal after 60 min. nPLA (0.075-0.25 μg/g body weight) was injected intravenously via the femoral vein at various times of post-occlusion.
Recombinant tissue plasminogen activator (tPA; Boehringer Ingelheim, Germany) was infused intravenously at a concentration of 10 μg/g body weight over a period of 60 min, starting 30 min post-occlusion. MK801 (Sigma-Aldrich Co., USA) was administered intraperitoneally in 3 doses: 2.5 μg/g body 30 min prior to MCAo followed by 1.25 μg/g body weight at 6 and 14 hr post-occlusion. Corresponding controls were treated with sterile saline and all animals were sacrificed after a total of 24 hr reperfusion period.
Whole brains were rapidly removed and snap-frozen in liquid nitrogen. Frozen brains were stored at -80°C until use. Consequently, there were 5 treatment groups:  Sham-operated (sham-op, n = 7);  Transient MCAo (MCAo) for 60 min and administered with 100 μl saline (MCAo, n = 10);  Transient MCAo for 60 min and administered with nPLA intravenously (MCAo+nPLA, n = 20);  Transient MCAo for 60 min and administered with tPA intravenously (n = 6);  Transient MCAo for 60 min and administered with MK801 intraperitoneally (n = 6).
Quantitation of the ischemic infarct volume
Whole rat brains were sliced coronally into 1 mm slices and incubated in 2, 3, 5-triphenyltetrazolium chloride (TTC; Sigma, St Louis, MO, USA) and fixed in 10% buffered formalin. Stained brain slices were scanned and the image was analysed using Scion Image analysis software for measurement of the infarct volume. The infarct size was determined according to Engelhorn et al . Histopathological changes in the brains were evaluated from paraffin embedded brain slices. Cell morphology assessment was carried out using the haematoxylin and eosin staining. The degree of apoptotic neuronal cell death was assessed by TUNEL staining using the ApopTag® Peroxidase In situ Apoptosis Detection kit (Chemicon International, USA) according to manufacturer's protocol.
RNA isolation and real-time quantitative PCR
Total RNA was isolated from brain tissues (frozen or fresh) by a single-step method using TRIzol® Reagent (Invitrogen, USA). The RNA samples were treated with RNase-free DNase at 37°C for 20 min and stored at -80°C until further use. Reverse transcription of total RNA and real-time PCR studies using SYBR-Green chemistry (Applied Biosystems, USA) were carried out according to Cher et al . A dissociation protocol was carried out at the end of each experiment that was performed in triplicates and repeated at least 3 times for each case.
Organotypic hippocampal slice culture
Organotypic hippocampal slice cultures were prepared as described previously  with slight modifications. Briefly, hippocampii from 6 to 8 days old Sprague Dawley rat pups were dissected and sliced to 350 μm thickness and placed in ice-cold growth medium (50% MEM, 25% HBSS, 25% heat inactivated horse serum, 5 mg/mL glucose, 1 mM glutamine, 1.5% fungizone). The sliced tissues were placed onto semiporous membranes (culture plate inserts; Millicell, Milipore Co, Bedford, MA) and grown for 10 to 14 days at 37°C with 5% CO2 enriched atmosphere before subjecting to oxygen and glucose deprivation (OGD) studies. Propidium iodide (PI; 5 μg/ml) was included in the culture media during the experiments to trace the damage on the tissues.
Oxygen-glucose deprivation (OGD)-mediated ischemic injury
Organotypic hippocampal cultures were grown in basal medium (75% MEM, 25% HBSS, 1 mM glutamine, and 1.0% penicillin-streptomycin) and transferred to six-well plates containing glucose-free medium (75% glucose-free MEM, 25% HBSS, 1 mM glutamine and 1.0% penicillin-streptomycin) saturated with 95% N2, 5%CO2 and placed into an anaerobic chamber at 37°C and 100% humidity for 90 mins. nPLA (0.0375 μM, 0.075 μM and 0.15 μM), was dissolved in distilled water and added to the medium immediately before exposure to OGD. After 90 mins, the cultures (culture plate semiporous inserts) were then transferred to a fresh 6 well plate containing pre-warmed serum free medium with 5 μg/mL propidium iodide  and incubated in the CO2 chamber for 24 hours. The hippocampal slices were viewed under confocal microscope and analysis of damaged CA1 hippocampal neurons following OGD was carried out using ImagePro Plus Software (Media Cybernetics, Silver Spring, MD, U.S.A.). Hippocampal culture in serum free media was used as controls in all experiments.
Astrocytoma (CRL1718™) cell culture
The human astrocytoma cells (CRL-1718™, ATCC) were cultured in RPMI 1640 media (Hyclone Laboratories, USA) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% Penicillin-streptomycin (GIBCO-BRI, Gaithersburg MD, USA) and maintained in a 37°C incubator with 5% CO2. Cells were checked regularly under the light microscope and were divided into appropriate culture plates when they reached 70-80% confluence. Cells were subcultured at a density of 1.0 × 105 cells (24-well plates) or 1.25 × 104 cells (96-well plates) as required and subjected to either staurosporine or OGD treatment(s).
Detection of TNF-α, cytotoxicity assay and caspase assay
Detection of TNF-α (inflammation marker) in the blood serum of rats subjected to MCAo (treated with either nPLA or LPS) was carried out using the Chemikine™ Rat TNFα Sandwich ELISA kit (Chemicon International, USA) according to manufacturer's protocol. Blood samples from Sprague Dawley rats (n = 6) with and without MCAo were administered intravenously with saline (100 μl) or nPLA (0.15 μg/g body weight) or intraperitoneally with bacterial lipopolysaccharide (LPS; 2 μg/g body weight). LPS was used as a positive control to induce inflammation and for the release of TNF-α.
In organotypic hippocampal slice culture studies, cell death measurement was carried out using the lactate dehydrogenase (LDH) assay (Roche Life Science, Germany). Briefly, the LDH activity in the culture media was measured spectrophotometrically at 490 nm using a multi-plate scanning spectrophotometer (Model 680 Microplate Reader, Bio-Rad Laboratories, CA) at an end point of 30 min. Caspase-3-like protease activity was measured by fluorometric assay (Axxora Life Sciences Inc., USA). DEVD-AFC was used as substrate for caspase activity of the cell lysate and the cleaved AFC (7-amino-4-trifluoro-methyl coumarin) was measured in a spectrofluorometer at 400/505 nm (excitation/emission).
Total RNA isolated from sham, MCAo and MCAo+nPLA brains was pooled to minimize inter-individual variation and hybridized to each array of the RAE-230A or U34A GeneChip™ according to protocols described in the GeneChip™ expression analysis package (Affymetrix, CA). Each chip represented ~15,900 genes and ESTs and data for each treatment were scaled to an average intensity of 800. Probe sets designated 'absent' in all treatments by the analysis software were discarded and only genes whose expressions were changed by 0.6-fold or greater in each pairwise comparison (between sham-op and MCAo or between MCAo and MCAo+nPLA) were deemed significant. Differentially expressed genes (p < 0.025) were classified according to their biological functions as described in the NetAffx Analysis Center http://www.affymetrix.com/analysis/index.affx and PubMed http://www.ncbi.nlm.nih.gov databases. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus  and are accessible through GEO Series accession number GSE17929, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17929.
All statistical analysis was carried out using single-factor ANOVA followed by (a) Dunnett multiple comparison tests for MCAo brain slice analysis and (b) for all other in vitro experiments, pairwise comparisons were carried out using unpaired Student's t-test.
nPLA reduces infarct volume in MCAo rat model
The nPLA native protein, was purified from Naja sputatrix according to the methods described by Armugam et al . The purity and identity of this protein was confirmed by mass spectrometry and N-terminal sequencing before using in this study. Naja sputatrix venom contains three (2 neutral and 1 acidic) isoforms of PLA2. Their molecular mass is approximately 14 kDa and all of them have anticoagulant and phospholipase activity . Among them, the nPLA is a most potent anticoagulant, with an enzymic activity and also competes with atropine for the muscarinic receptor .
Reduction in apoptotic cell death upon nPLA treatment
nPLA-mediated neuroprotection in in vitro studies
Global gene expression analysis
Global gene expression analysis by oligonucleotide microarray in MCAo and MCAo+nPLA showed a total of 1455 genes (filtering criteria; 0.6<SLR<-0.6 and detection p value < 0.025).
The microarray dataset when clustered by k-means clustering using the Genesis software package  gave 15 clusters of which clusters 1 and 6 (see Additional file 2) represented the genes that were fully restored to sham levels following nPLA treatment (see Additional file 3 &4).
The genes in cluster 1 (downregulated) and cluster 6 (upregulated) during MCAo revert to normal (Sham) level of expression upon nPLA treatment. The gene ontology classes can also be seen to be quite similar in both clusters 1 & 6. The major sites (cellular component) of action of nPLA appear to be the membrane and nucleus, implicating involvement of receptors and signaling pathways. This is further observed in pathway analysis using Gene Ontology (GO) and GENMAPP program  where most of the pathways involved are signalling pathways. Cluster 6 contains genes that are localized in the ribosome as well.
Nucleotide binding (ATP binding) is the most common functional GO class found for both clusters. Interestingly there are several ion binding related GO classes such as calcium and zinc ion binding that are common to both clusters, implicating the involvement of nPLA in the regulation of ionic levels of the cells. G-protein coupled receptor (GPCR) protein signalling pathway and intracellular protein transport are among the several common processes that were observed in both the clusters 1 & 6.
The pathways involved in apoptosis (Epithelial growth factor receptor (EGFR) 1, TNF-alpha-NF-kB and MAPK signalling pathways) and inflammation (Interleukin and T-cell receptor and B-cell receptor signalling pathways), were observed to be highly affected by nPLA treatment in MCAo rats. NFκB1 which is upregulated in nPLA treatment directly inhibits apoptosis (see Additional file 5). EGFR1 pathway regulates apoptosis and many genes of this pathway can be seen in clusters 1 and 6 (see Additional file 6). Hspa1a also known as HSP70 that inhibits apoptosis was found to be further upregulated upon nPLA treatment than MCAo (see Additional file 7). NFkb1 which is upregulated only in nPLA treatment is known to enhance cell survival. Thus, nPLA treatment appeared to protect the cell by anti-apoptotic as well as cell survival mechanisms.
nPLA reduces infarct volume and protects neurons from cell death
In this report, we demonstrate that nPLA could reduce apoptotic cell death and render neuroprotection against cerebral ischemia. Intravenous administration of nPLA to the MCAo rats at 0 min and 5 min post-occlusion reduced infarct volumes to 33.2% and 78.3% respectively as compared to the vehicle control. Saluja et al  observed significant increase in cPLA2 activity and expression after 10 mins and 20 mins upon onset of global ischemia. Furthermore, in an in vitro study, cPLA2 activity was not detected in the absence of calcium ion . Thus, these reports could explain our observation that administration of nPLA at only 0 min (initiation of occlusion) and 5 mins and not after 15 mins of occlusion, showed neuroprotection in our rat MCAo model. Significant reduction in ischemic damage has also been observed in histological analysis of the brain slices, where many cell nuclei exhibited normal morphology in nPLA treated MCAo rat brain. Neurons within the ischemic core die largely by means of a necrotic mechanism as a result of the excitotoxicity cascade triggered by energy depletion while damage within the penumbra is mediated by mechanisms such as apoptosis. During cerebral ischemia, sub-lethal injury to neurons favours the initiation of apoptosis in the penumbral neurons . The nPLA-mediated protection has been found to target the area/region where cells are undergoing apoptosis and consequently reducing cell death as observed in the TUNEL assay. Daniel and DeCoster  have demonstrated that TUNEL staining could be used as apoptosis marker and is significant at later times (>4 hr and <26 hr) of cell death. Hence, nPLA appears to possess the ability to protect, possibly the penumbra region from ischemic damage. Furthermore, nPLA-mediated 'protection' was also observed in human astrocytoma cells (CRL-1718™) exposed to staurosporine (STS) where increased cell viability and reduction in caspase 3 activity was observed upon nPLA treatment (Figure 3a &3b). Furthermore, significant reduction in FITC-Annexin V stained cells were observed in the astrocytoma exposed to STS and treated with 0.01 μM nPLA. Hoechst33342 staining showed that lesser number of DNA fragmentation occurs in the presence of nPLA. Thus indicating that nPLA could be mediating cell protection by reducing the apoptotic cell death.
Hippocampal slice cultures subjected to OGD also showed that 0.037 μM nPLA promoted about 60% and 95% survival at the CA1 and CA3 regions respectively, whereas 0.075 μM nPLA showed 95% protection for both regions. The protection mediated by nPLA (0.075 μM) was similar to that observed for MK801, a selective non-competitive antagonist of NMDA receptor. MK801 was used as a positive control for neuroprotection as it has been shown to be highly neuroprotective in both models of ischemia and hypoxia [37, 38]. We have also observed that the protection shown in the presence of nPLA is solely mediated by nPLA and not by intracellular PLA2 (iPLA2, cPLA2 or sPLA2). This is also because (a) similar protection could not be observed in the vehicle treated control slices subjected to OGD and (b) the endogenous PLA2s are known to mediate cell death rather than protection in organotypic hippocampal slice cultures subjected to OGD [11, 13, 14].
Gilroy et al  have also demonstrated that iPLA2 is highly expressed at the onset phase of an acute inflammation with comparatively lower levels of sPLA2 (Groups 2A and 5) as well as cPLA2 (Group 4) while the sPLA2 and cPLA2 were the predominant isoforms expressed during lesion resolution. Inhibition of both the cPLA and iPLA has been proposed to be beneficial in reducing infarct volume and increasing the neurological activities of mice subjected to MCAo [10, 12] as well as increasing survival and neuroprotection in in vitro experiments [11, 13]. The global gene expression data show that nPLA administration during MCAo reduces the iPLA2 but increases the cPLA2 and sPLA2 expression (1B, 2A, 2B). In contrast to the general observation that endogenous PLA2 promotes pathophysiological condition, Forlenza et al  reported that reduced endogenous PLA2 (cPLA and iPLA) activity could impair neuronal viability and the functional integrity of both calcium-dependent and calcium-independent cytosolic PLA2. Endogenous sPLA2-X and human sPLA2-III have been reported to promote neurite outgrowth in PC12 cells [41, 42], an effect that is not observed with the administration of sPLA-1B or sPLA-IIA. It is noteworthy that the nPLA belongs to the group 1A (sPLA-IA) which is similar to the sPLA-1B but without the signature pancreatic loop.
We have also shown that nPLA could protect cell death induced by glutamate (see Additional file 8) in the hippocampal slice culture as well as in the astrocytoma cell culture (CRL-1718™; Figure 2d-f). Furthermore, in a separate in vitro study on astrocytes and hippocampii using glutamate receptor agonists and antagonists as well as an inhibitor to phospholipase activity (4-bromophenacyl bromide), we have found that the nPLA mediated neuroprotection is exerted via the mGluR, specifically mGluR1 and not by its phospholipase activity (unpublished data).
Quantitative gene expression analysis on the MCAo (+nPLA) ipsilateral brain (Figure 2c) and hippocampal tissues subjected to OGD (+nPLA) (Figure 4c) showed that the pro-survival (NFκB) and anti-apoptotic (Bcl-2 and Bcl-XL) genes were up-regulated while the pro-apoptotic Bax gene was down-regulated upon nPLA administration in both the in vivo and in vitro studies. Bax homodimer has been reported to activate apoptosis while the heterodimer (with Bcl-2 or Bcl-XL) is known to inhibit the process . Elevated intracellular ratio of Bax to Bcl-2 occurs during increased apoptotic cell death . Similarly, over-expression of Bcl-2 in in vivo ischemic studies resulted in reduced apoptotic cell death [45, 46]. Hence, the quantitative real-time PCR results on the brain sample subjected to MCAo and hippocampal slice culture subjected to OGD, further support that apoptotic cell death is reduced upon treatment with nPLA. The high expression of both anti-apoptotic genes (Bcl-2 and Bcl-XL), could possibly result in Bax/Bcl-2 or Bcl-XL heterodimerization, thereby inhibiting apoptosis and promoting neuroprotection. Similarly, Neuroprotectin D1, derivative of docosahexaenoic acid (DHA), that promotes strong neuroprotection and neurotrophic activity following ischemia and reperfusion, also up-regulates Bcl-2 and Bcl-xL. Neuroprotectin D1 was also observed to inhibit the caspase-3 activation . However, nPLA improved cell viability and survival in astrocytoma cells subjected to OGD. The increase in cell viability was accompanied by significant reduction in caspase-3 activity.
Consistently, reduction in caspase activity and increased in cell viability have also been observed in staurosporine-mediated apoptosis in astrocytoma cells treated with nPLA (Figure 3a&3b). Oligonucleotide/DNA microarray analysis also suggests that nPLA treatment in MCAo rats reduce the impact of MCAo-mediated cellular damage to normal (sham) level via inhibiting or reducing the effect of apoptosis and inflammatory mechanisms, thus supporting an anti-apoptotic regulation as a possible mechanism of action for nPLA-mediated neuroprotection, which is also consistent with our TUNNEL assays and Real-time PCR analysis.
Regulation of water and ion channel genes
Apoptotic volume decrease (AVD), the earliest morphological event of apoptosis that is depicted by pronounced cell shrinkage is believed to involve regulation of water and ion channels. During AVD, intracellular ion concentrations are altered following inhibition of Na+/K+ATPase in conjunction with a transient Na+ accumulation followed by the extrusion of both Na+ and K+ ions from the cell. Decreased intracellular K+ is in turn required for the activation of the apoptotic/caspase cascade and optimal nuclease activity . Water movement during the AVD is mediated primarily via aquaporins and that plasma membrane water permeability directly affects the rate of apoptotic progression . Aquaporins have been shown to play a pivotal role in the formation and clearance of fluid (brain edema) during cerebral ischemia. The Aqp4 is a water specific mercury insensitive water channel that is found abundantly in brain and the Aqp9 is an aquaglyceroporin that conducts urea, lactate, arsenite, purine and pyrimidines, besides water molecule . Aquaporin 4 and 9 have been shown to be down-regulated in experimental ischemic rat brain, while the Aqp4 knockout mice subjected to MCAo showed smaller infarct volume. The regression of ischemic infract also required an up-regulation of Aqps . Interestingly, in our study, both these aquaporins (Aqp4 and 9) were up-regulated upon nPLA administration. Up-regulation of Aqp9 therefore suggests that the lactate and other solutes that were formed during the ischemic injury may be channelled out of the cell via Aqp9, thus could prove beneficial in neuroprotection. Notably, the Kir4.1 and Na+/K+ATPase genes were also upregulated upon nPLA administration in the MCAo rat. Similarly, we have also observed that expression of the aquaporin genes as well as the Kir4.1 and Na+/K+ATPase in astrocytoma cells subjected to OGD (2 hr) were reversed in the presence of nPLA. Expression of genes involved in cell survival promoting pathway (PI3K, ERK1 and NFkB) have also been significantly upregulated with nPLA administration, indicating that an anti-apoptotic, homeostatic (ionic/physiologic) and cell survival regulation are being triggered in nPLA-mediated neuroprotection.
Snake venom PLA2 is known for its pathopharmacological activities. We have shown here that nPLA, a potent toxin isolated from Naja sputatrix venom, could reduce neuronal cell death and promote cell survival both under in vivo and in vitro ischemic conditions. Its beneficial effects could be seen at a sublethal in vivo dose of 0.15 μg/g rats (0.25 LD50) and at a concentration of 0.15 μM under in vitro conditions.
This work was supported by research grants from the Academic Research Fund (R183-000-222-101, -162-112 and -126-112) from the National University of Singapore.
- Dennis EA: Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem. 1994, 269: 13057-60.PubMedGoogle Scholar
- Cummings BS, McHowat J, Schnellmann RG: Phospholipase A(2)s in cell injury and death. J Pharmacol Exp Ther. 2000, 294: 793-9.PubMedGoogle Scholar
- Winstead MV, Balsinde J, Dennis EA: Calcium-independent phospholipase A(2): structure and function. Biochim Biophys Acta. 2000, 1488: 28-39.View ArticlePubMedGoogle Scholar
- Kudo I, Murakami M: Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69: 3-58. 10.1016/S0090-6980(02)00020-5.View ArticlePubMedGoogle Scholar
- Sun GY, Xu J, Jensen MD, Simonyi A: Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res. 2004, 45: 205-13. 10.1194/jlr.R300016-JLR200.View ArticlePubMedGoogle Scholar
- Liu NK, Zhang YP, Titsworth WL, Jiang X, Han S, Lu PH, Shields CB, Xu XM: A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol. 2006, 59: 606-19. 10.1002/ana.20798.View ArticlePubMedGoogle Scholar
- Sun GY, Xu J, Jensen MD, Yu S, Wood WG, Gonzalez FA, Simonyi A, Sun AY, Weisman GA: Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol Neurobiol. 2005, 31: 27-41. 10.1385/MN:31:1-3:027.View ArticlePubMedGoogle Scholar
- Farooqui AA, Ong WY, Horrocks LA: Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev. 2006, 58: 591-620. 10.1124/pr.58.3.7.View ArticlePubMedGoogle Scholar
- Moses GS, Jensen MD, Lue LF, Walker DG, Sun AY, Simonyi A, Sun GY: Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation. 2006, 3: 28-10.1186/1742-2094-3-28.PubMed CentralView ArticlePubMedGoogle Scholar
- Muralikrishna Adibhatla R, Hatcher JF: Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med. 2006, 40: 376-87. 10.1016/j.freeradbiomed.2005.08.044.View ArticlePubMedGoogle Scholar
- Arai K, Ikegaya Y, Nakatani Y, Kudo I, Nishiyama N, Matsuki N: Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability. Eur J Neurosci. 2001, 13: 2319-23. 10.1046/j.0953-816x.2001.01623.x.View ArticlePubMedGoogle Scholar
- Tabuchi S, Uozumi N, Ishii S, Shimizu Y, Watanabe T, Shimizu T: Mice deficient in cytosolic phospholipase A2 are less susceptible to cerebral ischemia/reperfusion injury. Acta Neurochir Suppl. 2003, 86: 169-72.PubMedGoogle Scholar
- Strokin M, Chechneva O, Reymann KG, Reiser G: Neuroprotection of rat hippocampal slices exposed to oxygen-glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of docosahexaenoic acid-containing phospholipids by calcium independent phospholipase A2. Neuroscience. 2006, 140: 547-53. 10.1016/j.neuroscience.2006.02.026.View ArticlePubMedGoogle Scholar
- Gabryel B, Chalimoniuk M, Stolecka A, Langfort J: Activation of cPLA2 and sPLA2 in astrocytes exposed to simulated ischemia in vitro. Cell Biol Int. 2007, 31: 958-65. 10.1016/j.cellbi.2007.03.005.View ArticlePubMedGoogle Scholar
- Harris JB, Grubb BD, Maltin CA, Dixon R: The neurotoxicity of the venom phospholipases A(2), notexin and taipoxin. Exp Neurol. 2000, 161: 517-26. 10.1006/exnr.1999.7275.View ArticlePubMedGoogle Scholar
- Miyoshi S, Tu AT: Muscarinic acetylcholine receptor (mAChR) inhibitor from snake venom: interaction with subtypes of human mAChR. Arch Biochem Biophys. 1999, 369: 114-8. 10.1006/abbi.1999.1321.View ArticlePubMedGoogle Scholar
- Valentin E, Lambeau G: What can venom phospholipases A(2) tell us about the functional diversity of mammalian secreted phospholipases A(2)?. Biochimie. 2000, 82: 815-31. 10.1016/S0300-9084(00)01168-8.View ArticlePubMedGoogle Scholar
- Armugam A, Earnest L, Chung MC, Gopalakrishnakone P, Tan CH, Tan NH, Jeyaseelan K: Cloning and characterization of cDNAs encoding three isoforms of phospholipase A2 in Malayan spitting cobra (Naja naja sputatrix) venom. Toxicon. 1997, 35: 27-37. 10.1016/S0041-0101(96)00071-2.View ArticlePubMedGoogle Scholar
- Jeyaseelan K, Armugam A, Donghui M, Tan NH: Structure and phylogeny of the venom group I phospholipase A(2) gene. Mol Biol Evol. 2000, 17: 1010-21.View ArticlePubMedGoogle Scholar
- Tan NH, Arunmozhiarasi A: The anticoagulant activity of Malayan cobra (Naja naja sputatrix) venom and venom phospholipase A2 enzymes. Biochem Int. 1989, 19: 803-10.PubMedGoogle Scholar
- Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989, 20: 84-91.View ArticlePubMedGoogle Scholar
- Engelhorn T, Doerfler A, Forsting M, Heusch G, Schulz R: Does a relative perfusion measure predict cerebral infarct size?. AJNR Am J Neuroradiol. 2005, 26: 2218-23.PubMedGoogle Scholar
- Cher CD, Armugam A, Lachumanan R, Coghlan MW, Jeyaseelan K: Pulmonary inflammation and edema induced by phospholipase A2: global gene analysis and effects on aquaporins and Na+/K+-ATPase. J Biol Chem. 2003, 278: 31352-60. 10.1074/jbc.M302446200.View ArticlePubMedGoogle Scholar
- Stoppini L, Buchs PA, Muller D: A simple method for organotypic cultures of nervous tissue. J Neurosci Methods. 1991, 37: 173-82. 10.1016/0165-0270(91)90128-M.View ArticlePubMedGoogle Scholar
- Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl Acids Res. 2002, 30: 207-10. 10.1093/nar/30.1.207.PubMed CentralView ArticlePubMedGoogle Scholar
- Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, Lo EH: Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1999, 19: 1316-21. 10.1097/00004647-199912000-00004.View ArticlePubMedGoogle Scholar
- Kilic E, Bahr M, Hermann DM: Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke. 2001, 32: 2641-7. 10.1161/hs1101.097381.View ArticlePubMedGoogle Scholar
- Bertorelli R, Adami M, Di Santo E, Ghezzi P: MK 801 and dexamethasone reduce both tumor necrosis factor levels and infarct volume after focal cerebral ischemia in the rat brain. Neurosci Lett. 1998, 246: 41-4. 10.1016/S0304-3940(98)00221-3.View ArticlePubMedGoogle Scholar
- Adibhatla RM, Hatcher JF: Secretory phospholipase A2 IIA is up-regulated by TNF-alpha and IL-1alpha/beta after transient focal cerebral ischemia in rat. Brain Res. 2007, 1134: 199-205. 10.1016/j.brainres.2006.11.080.PubMed CentralView ArticlePubMedGoogle Scholar
- Van Cruchten S, Broeck Van Den W: Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 2002, 31: 214-23. 10.1046/j.1439-0264.2002.00398.x.View ArticlePubMedGoogle Scholar
- Sturn A, Quackenbush J, Trajanoski Z: Genesis: cluster analysis of microarray data. Bioinformatics. 2002, 18: 207-8. 10.1093/bioinformatics/18.1.207.View ArticlePubMedGoogle Scholar
- Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR: GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 2002, 31: 19-20. 10.1038/ng0502-19.View ArticlePubMedGoogle Scholar
- Saluja I, O'Regan MH, Song D, Phillis JW: Activation of cPLA2, PKC, and ERKs in the rat cerebral cortex during ischemia/reperfusion. Neurochem Res. 1999, 24: 669-77. 10.1023/A:1021004525979.View ArticlePubMedGoogle Scholar
- Glover S, de Carvalho MS, Bayburt T, Jonas M, Chi E, Leslie CC, Gelb MH: Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. J Biol Chem. 1995, 270: 15359-67. 10.1074/jbc.270.25.15359.View ArticlePubMedGoogle Scholar
- Smith WS: Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol. 2004, 15: S3-12.View ArticlePubMedGoogle Scholar
- Daniel B, DeCoster MA: Quantification of sPLA2-induced early and late apoptosis changes in neuronal cell cultures using combined TUNEL and DAPI staining. Brain Res Brain Res Protoc. 2004, 13: 144-50. 10.1016/j.brainresprot.2004.04.001.View ArticlePubMedGoogle Scholar
- Pringle AK, Iannotti F, Wilde GJ, Chad JE, Seeley PJ, Sundstrom LE: Neuroprotection by both NMDA and non-NMDA receptor antagonists in in vitro ischemia. Brain Res. 1997, 755: 36-46. 10.1016/S0006-8993(97)00089-9.View ArticlePubMedGoogle Scholar
- Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL: The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA. 1986, 83: 7104-8. 10.1073/pnas.83.18.7104.PubMed CentralView ArticlePubMedGoogle Scholar
- Gilroy DW, Newson J, Sawmynaden P, Willoughby DA, Croxtall JD: A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. Faseb J. 2004, 18: 489-98. 10.1096/fj.03-0837com.View ArticlePubMedGoogle Scholar
- Forlenza OV, Mendes CT, Marie SK, Gattaz WF: Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukot Essent Fatty Acids. 2007, 76: 47-55. 10.1016/j.plefa.2006.10.002.View ArticlePubMedGoogle Scholar
- Masuda S, Yamamoto K, Hirabayashi T, Ishikawa Y, Ishii T, Kudo I, Murakami M: Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival. Biochem J. 2008, 409: 429-38. 10.1042/BJ20070844.View ArticlePubMedGoogle Scholar
- Ikeno Y, Konno N, Cheon SH, Bolchi A, Ottonello S, Kitamoto K, Arioka M: Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem. 2005, 280: 28044-52. 10.1074/jbc.M503343200.View ArticlePubMedGoogle Scholar
- Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science. 1998, 281: 1322-6. 10.1126/science.281.5381.1322.View ArticlePubMedGoogle Scholar
- Zha H, Reed JC: Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem. 1997, 272: 31482-8. 10.1074/jbc.272.50.31482.View ArticlePubMedGoogle Scholar
- Kitagawa K, Matsumoto M, Tsujimoto Y, Ohtsuki T, Kuwabara K, Matsushita K, Yang G, Tanabe H, Martinou JC, Hori M, et al.: Amelioration of hippocampal neuronal damage after global ischemia by neuronal overexpression of BCL-2 in transgenic mice. Stroke. 1998, 29: 2616-21.View ArticlePubMedGoogle Scholar
- Wang HD, Fukuda T, Suzuki T, Hashimoto K, Liou SY, Momoi T, Kosaka T, Yamamoto K, Nakanishi H: Differential effects of Bcl-2 overexpression on hippocampal CA1 neurons and dentate granule cells following hypoxic ischemia in adult mice. J Neurosci Res. 1999, 57: 1-12. 10.1002/(SICI)1097-4547(19990701)57:1<1::AID-JNR1>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
- Bazan NG: Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005, 15: 159-66.View ArticlePubMedGoogle Scholar
- Maeno E, Ishizaki Y, Kanaseki T, Hazama A, Okada Y: Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci USA. 2000, 97: 9487-92. 10.1073/pnas.140216197.PubMed CentralView ArticlePubMedGoogle Scholar
- Jablonski EM, Webb AN, McConnell NA, Riley MC, Hughes FM: Plasma membrane aquaporin activity can affect the rate of apoptosis but is inhibited after apoptotic volume decrease. Am J Physiol Cell Physiol. 2004, 286: C975-85. 10.1152/ajpcell.00180.2003.View ArticlePubMedGoogle Scholar
- Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS: Molecular mechanisms of brain tumor edema. Neuroscience. 2004, 129: 1011-20. 10.1016/j.neuroscience.2004.05.044.View ArticlePubMedGoogle Scholar
- Kobayashi H, Yanagita T, Yokoo H, Wada A: Molecular mechanisms and drug development in aquaporin water channel diseases: aquaporins in the brain. J Pharmacol Sci. 2004, 96: 264-70. 10.1254/jphs.FMJ04004X5.View ArticlePubMedGoogle Scholar
- Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et al.: TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003, 34: 374-8.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.